Retrieve an updated list of publications from PubMed by clicking on this link.


Levy T#, Voeltzke K#, Hauffe L#, Alasad K#, Snaebjörnsson M, Marciano R, Scharov K, Planque M, Vriens K, Christen S, Funk CM, Hassiepen C, Kahler A, Heider B, Picard D, Lim JKM, Bas Z, Bendrin K, Vargas-Toscano A, Kahlert U, Remke M, Elkabets M, GP Grünewald TGP, Reichert AS, Fendt S-M, Schulze A, Reifenberger G, Rotblat B*, Leprivier G*.
4EBP1/2 support cell survival during energetic stress by translationally regulating fatty acid synthesis. bioRxiv 2022.09.09.507243; doi: #co-first authors; *co-last authors.

Bartl J, Zanini M, Bernardi F, Forget A, Blümel L, Talbot J, Picard D, Qin N, Cancila G, Gao Q, Nath S, Koumba IM, Wolter M, Kuonen F, Langini M, Beez T, Munoz C, Pauck D, Marquardt V, Yu H, Souphron J, Korsch M, Mölders C, Berger D, Göbbels S, Meyer FD, Scheffler B, Rotblat B, Diederichs S, Ramaswamy V, Suzuki H, Oro A, Stühler K, Stefanski A, Fischer U, Leprivier G, Willbold D, Steger G, Buell A, Kool M, Lichter P, Pfister SM, Northcott PA, Taylor MD, Borkhardt A, Reifenberger G, Ayrault O, Remke M.
The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. Nat Commun. 2022 Jul 13;13(1):4061.

Voeltzke K, Scharov K, Funk CM, Kahler A, Picard D, Hauffe L, Orth MF, Remke M, Esposito I, Kirchner T, Schramm A, Rotblat B, Grünewald TGP, Reifenberger G, Leprivier G.
EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma. Cell Death Discov. 2022 Apr 4;8(1):157.

Hauffe L, Picard D, Musa J, Remke M, Grünewald TGP, Rotblat B, Reifenberger G, Leprivier G.
Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation. Cell Death Discov. 2022 Feb 28;8(1):91.


Ahmadov U, Picard D, Bartl J, Silginer M, Trajkovic-Arsic M, Qin N, Blümel L, Wolter M, Lim JKM, Pauck D, Winkelkotte AM, Melcher M, Langini M, Marquardt V, Sander F, Stefanski A, Steltgens S, Hassiepen C, Kaufhold A, Meyer FD, Seibt A, Kleinesudeik L, Hain A, Münk C, Knobbe-Thomsen CB, Schramm A, Fischer U, Leprivier G, Stühler K, Fulda S, Siveke JT, Distelmaier F, Borkhardt A, Weller M, Roth P, Reifenberger G, Remke M.
The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. Cell Death Dis. 2021 Sep 28;12(10):885.


Alasad K, Voeltzke K, Levin L, Reifenberger G, Leprivier G, Rotblat B.
4EBP1/2 are active under standard cell culture conditions to regulate the translation of specific mRNAs. Cell Death Dis. 2020 Nov 11;11(11):968.
Leprivier G, Rotblat B.
How does mTOR sense glucose starvation? AMPK is the usual suspect. Cell Death Discov. 2020 Apr 22;6:27.


Lim JKM, Leprivier G.
The impact of oncogenic RAS on redox balance and implications for cancer development. Cell Death Dis. 2019 Dec 18;10(12):955.

Lim JKM, Leprivier G, Sorensen PH.
RAS-driven oncogenesis is supported by downstream antioxidant programs. Mol Cell Oncol, 2019 Nov 10;7(1):1654814.

Varon M, Levy T, Mazor G, Ben David H, Marciano R, Krelin Y, Prasad M, Elkabets M, Pauck D, Ahmadov U, Picard D, Qin N, Borkhardt A, Reifenberger G, Leprivier G, Remke M, Rotblat B.
The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cells. Int J Cancer, 2019 May 13.

Lim JKM, Delaidelli A, Minaker SW, Zhang HF, Colovic M, Yang H, Negri GL, von Karstedt S, Lockwood WW, Schaffer P, Leprivier G*, Sorensen PH*.
Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A, 2019 May 7;116(19):9433-9442. *Co-senior authorship.

Mazor G, Levin L, Picard D, Ahmadov U, Carén H, Borkhardt A, Reifenberger G, Leprivier G, Remke M, Rotblat B.
The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death Dis, 2019 Mar 13;10(3):246.

Marciano R, Prasad M, Levy T, Tzadok S, Leprivier G, Elkabets M, Rotblat B.
High-Throughput Screening Identified Compounds Sensitizing Tumor Cells to Glucose Starvation in Culture and VEGF Inhibitors In Vivo. Cancers, 2019 Jan 30;11(2).


Marciano R, Leprivier G, Rotblat B.
Puromycin labeling does not allow protein synthesis to be measured in energy-starved cells. Cell Death Dis, 2018 Jan 18;9(2):39.


Delaidelli A, Leprivier G, Sorensen PH.
eEF2K protects MYCN-amplified cells from starvation. Cell Cycle, 2017 Sep 17;16(18):1633-1634.

Delaidelli A, Negri GL, Jan A, Jansonius B, El-Naggar A, Lim JKM, Khan D, Oo HZ, Carnie CJ, Remke M, Maris JM, Leprivier G, Sorensen PH.
MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation. Cell Death Differ, 2017 Sep;24(9):1564-1576.

Toiber D, Leprivier G, Rotblat B.
Long noncoding RNA: noncoding and not coded.
Cell Death Discov, 2017 Jan 9;3:16104.


Musa J, Orth M, Dallmayer M, Baldauf M, Pardo C, Rotblat B, Kirchner T, Leprivier G, Grunewald TG.
Eukaryotic initiation factor 4E binding protein 1 (4E-BP1): A master regulator of mRNA translation involved in tumorigenesis. Oncogene, 2016 Feb 1.


Leprivier G, Rotblat B, Khan D, Jan E, Sorensen PH.
Stress-mediated translational control in cancer cells. Biochim Biophys Acta - Gene Regulatory Mechanisms, 2015 Jul;1849(7):845-60.

El-Naggar AM, Veinotte CJ, Cheng H, Grunewald TGP, Negri GL, Somasekharan SP, Corkery DP, Tirode F, Mathers J, Khan D, Kyle AH, Baker JH, LePard NE, McKinney S, Hajee S, Bosiljcic M, Leprivier G, Tognon CE, Minchinton AI, Bennewith KL, Delattre O, Wang Y, Dellaire G, Berman JN, Sorensen PH.
Translational activation of HIF1α by YB-1 promotes sarcoma metastasis. Cancer Cell, 2015 May 11;27(5):682-97.

Somasekharan SP, El-Naggar A*, Leprivier G*, Cheng S, Hajee S, Grunewald TG, Zhang F, Ng T, Delattre O, Evdokimova V, Wang Y, Gleave M, Sorensen PH.
YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. J Cell Biol, 2015 Mar 30;208(7):913-29. *These authors contributed equally to the work.


Leprivier G, Sorensen PH.
How does oncogene transformation render tumor cells hypersensitive to nutrient deprivation? Bioessays, 2014 Nov;36(11):1082-90.

Rotblat B, Southwell AL, Ehrnhoefer DE, Skotte NH, Metzler M, Franciosi S, Leprivier G, Somasekharan SP, Barokas A, Deng Y, Tang T, Mathers J, Cetinbas N, Daugaard M, Kwok B, Li A, Carnie C, Fink D, Nitsch R, Galpin JD, Ahern CA, Melino G, Penninger J, Hayden MR, Sorensen PH.
HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proc Natl Acad Sci U S A, 2014 Feb 25;111(8):3032-7.


Rotblat B*, Grunewald TG*, Leprivier G*, Melino G, Knight RA.
Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers. Oncotarget, 2013 Dec;4(12):2577-90. *These authors contributed equally to the work.

Leprivier G, Rotblat B, Delattre O, Sorensen PH.
Rôle clé de la kinase eEF2K dans la survie cellulaire à la privation de nutriments [Surviving nutrient deprivation by restraining translation elongation: biological function of the eEF2 kinase]. Med Sci (Paris), 2013 Nov;29(11):951-3.

Cetinbas N, Huang-Hobbs H, Tognon C, Leprivier G, An J, McKinney S, Bowden M, Chow C, Gleave M, McIntosh LP, Sorensen PH.
Mutation of the salt bridge-forming residues in the ETV6-SAM domain interface blocks ETV6-NTRK3-induced cellular transformation. J Biol Chem, 2013 Sep 27;288(39):27940-50.

Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, Faubert B, Bridon G, Tognon CE, Mathers J, Thomas R, Li A, Barokas A, Kwok B, Bowden M, Smith S, Wu X, Korshunov A, Hielscher T, Northcott PA, Galpin JD, Ahern CA, Wang Y, McCabe MG, Collins VP, Jones RG, Pollak M, Delattre O, Gleave ME, Jan E, Pfister SM, Proud CG, Derry WB, Taylor MD, Sorensen PH.
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell, 2013 May 23;153(5):1064-79.


Somasekharan SP, Stoynov N, Rotblat B,  Leprivier G, Galpin JD, Ahern CA, Foster LJ, Sorensen PH.
Identification and quantification of newly synthesized proteins translationally regulated by YB-1 using a novel Click-SILAC approach. J Proteomics, 2012 Dec 21;77:e1-10.

Leprivier G, Rufini A, García-Sáez AJ, Borner C, Rotblat B.  7th Tuscany Retreat on Cancer Research: Genetic profiling, resistance mechanism and novel treatment concepts in cancer. Cell Death Differ, 2012 Mar;19(3):546-8.

Ng TL, Leprivier G, Robertson MD, Chow C, Martin MJ, Laderoute KR, Davicioni E, Triche TJ, Sorensen PH.
The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. Cell Death Differ, 2012 Mar;19(3):501-10.


Rotblat B, Leprivier G, Sorensen PH. A possible role for long non-coding RNA in modulating signaling pathways. Medical Hypothesis, 2011 Dec;77(6):962-5.


Choul-Li S, Leroy C, Leprivier G,  Laitem C, Tulasne D, Aumercier M.
Caspase cleavages of Ets-1 p51 generate fragments with transcriptional dominant-negative function. Biochem J, 2010 Feb 9; 426(2): 229-41.


Leprivier G, Baillat D, Begue A, Hartmann B, Aumercier M.
Ets-1 p51 and p42 isoforms differentially modulate Stromelysin-1 promoter according to induced DNA bend orientation. Nucleic Acids Res, 2009 Jul; 37(13): 4341-52.

Laitem C*, Leprivier G*, Choul-Li S, Begue A, Monte D, Larsimont D, Dumont P, Duterque-Coquillaud M, Aumercier M.
Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular localization of Ets-1 p51. Oncogene, 2009 May 21; 28(20): 2087-99. *These authors contributed equally to the work.

Baillat D*, Laitem C*, Leprivier G, Margerin C, Aumercier M.
Ets-1 binds cooperatively to the palindromic Ets-binding sites in the p53 promoter. Biochem Biophys Res Commun, 2009 Jan 9; 378(2): 213-7. *These authors contributed equally to the work.


Baillat D*, Leprivier G*, Régnier D, Vintonenko N, Bègue A, Stéhelin D, Aumercier M.
Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter. Oncogene, 2006 Sep 21; 25(42): 5764-76.*These authors contributed equally to the work.

MediathekInformation und Wissen
LageplanSo finden Sie uns